Share Name Share Symbol Market Type Share ISIN Share Description
Gyrus Group LSE:GYG London Ordinary Share GB0001701522 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 629.50p 0.00p 0.00p - - - 0 06:30:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services - - - - 931.73

Gyrus (GYG) Latest News

Real-Time news about Gyrus Grp (London Stock Exchange): 0 recent articles
More Gyrus News
Gyrus Takeover Rumours

Gyrus (GYG) Share Charts

1 Year Gyrus Chart

1 Year Gyrus Chart

1 Month Gyrus Chart

1 Month Gyrus Chart

Intraday Gyrus Chart

Intraday Gyrus Chart

Gyrus (GYG) Discussions and Chat

Gyrus Forums and Chat

Date Time Title Posts
31/1/200821:13Gyrus Group 2006291
18/7/200710:51Gyrus group.6
24/3/200620:47gyrus read this88
16/3/200511:17gryus read this-
05/2/200509:32gyrus group = strong buy183

Add a New Thread

Gyrus (GYG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Gyrus trades in real-time

Gyrus (GYG) Top Chat Posts

maddox: Rivaldo, Agreed, I would have expected anoter bidder to have thrown their hat into the ring by now. Also, the share price would have signalled an interest. This looks like a done deal. Regards, Maddox
rivaldo: The offer document's being published, so the Offer looks nailed on - getting a bit late for other approaches now. The share price should now approach the full 630p offered.
grigor: ... The offer, which values Gyrus at £935m, could be high enough to ward off interest from other bidders, although Paul Cuddon, an analyst at KBC Peel Hunt, said that Johnson & Johnson is unlikely to be comfortable with Olympus entering the market for general electrosurgical devices and may consider a counter-bid. Companies such as Stryker, ValleyLab and Pentax were also seen as possible suitors to rival the Japanese company's ambition. Mr Cudden said that some interested parties may have been surprised by the speed at which Olympus has done the deal, and that until the takeover completes, there is room for further share price upside. Any rival bid is likely could be complicated by the US regulators, due to the overlap in the major players' operations. The Nomura analyst Michael King said that the likes of Karl Storz, a leading supplier to the urology and gynaecology markets, may be interested in Gyrus, but the overlap may be too great for US regulators. For Olympus, the overlap between the two businesses is not as stark, with the Japanese company strongest in Japan and Europe, while Gyrus has a more dominant position in the US. ...
maddox: Wad, Not impressed by these results. I was expecting the dollar effect but the underlying growth is less than I expected. The share price fall also leads me to believe that they have not done anything to lower expectations ahead of these figures. With the Analysts giving a rosey picture, as Rivaldo has posted above, this disappointed reaction was a given. It doesn't pay to undermine the Analyst's confidence in the management team. Regards, Maddox
rivaldo: Stick with it wad collector imo - short-term is irrelevant if you're after decent gains of 50% or more as probably most of us on this thread have. For example, from yesterday: "Gyrus Posted on September 11th, 2007 in Market whispers. Morgan Stanley says the recent share price decline presents a buying opportunity. With a price target of 517p, broker says: 'Although Gyrus has experienced more than 10% share price decline in the last two months, we believe there is no fundamental reason for this.'"
rivaldo: Entj, I think you'll find FMR have actually top-sliced a few into the rise. Which makes the share price performance even more impressive. A snippet from the Mail today tells us a bit more about why JPM target 575p: "A JP Morgan recommendation helped Gyrus climb 27p to 515p. The broker says the company enjoys a core position in the US urology and gynaecology keyhole surgery market and is now entering the much larger surgery market."
rivaldo: Aha :o)) 575p here we come.... "Gyrus May 23rd, 2007 | Market whispers | No comments. JP Morgan likes the medical devices firm, which is actually a mini Smith & Nephew. It has initiated coverage of the stock with an overweight recommendation and 575p a share price target."
maddox: Wad, Hummmph, um not sure I actually gave advice, merely gave my own perspective. Anyway, I'm glad its worked out. Yep the Broker's recommendations are curious. I'm often perplexed by the 'buy'recommendation with a target that is one or two per cent ahead of the current share price. I saw one the other day that was a 'buy' and well below the current price? Your comment about valuations in the absence of a dividend is well made. However, I think its a question of whether they can make better use of the money than paying it out in dividends. I'd prefer to have capital growth than taxed dividends - at least in the short term. For example, if Gyrus are placing generators then the more capital they have available to do this the faster growth we will see. REgards, Maddox
wad collector: Yes , holding has been the right decision so far, but I get a bit nervous after steady rises.Gyrus share price is pretty hard to guage in absence of a dividend, so I feel it rides a lot on sentiment .My wifes broker (NatWest)bought more of these than I would have a few yrs ago, and finally is looking like a good buy.I will sell half at some point but am pleased I listened to your Hold advice last month.One problem I find with brokers targets is that they never specify a timescale .I predict Gyrus will be £10 , but may be several yrs!
maddox: Hi Guys, My investment style is long-term strategic. The current share price is by and large just market froth. This is a great company, with a sound strategy, a proven management team in a growing and expanding market. Everything else is largely irrelevant, including the dollar. You only need to look at the market trends, an aging affluent population; growing use of established keyhole surgery procedures (quicker, safer and more cost effective results); wider adoption of keyhole techniques to new procedures (e.g. general surgery); economic pressures on healthcare providers to move towards 'day case' provision. The share price will tend to move to either being above or below what can be taken to be fair value. It gives you the opportunity to either get in or get out at an acceptable price. The short term investment approaches essentially require you to try and second guess the market and avoid un-expected events (such as Dollar movements). The hair trigger investment style doesn't suit me, I've tried it and I cannot make it work. Regards, Maddox
Gyrus share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170629 10:57:22